NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

MGUS

Rifaximin in Patients With Monoclonal Gammopathy

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

IgA Monoclonal Gammopathy

IgG Monoclonal Gammopathy

IgM Monoclonal Gammopathy

Light Chain Deposition Disease

Monoclonal Gammopathy

Smoldering Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia

Gammopathy, Monoclonal

Gammopathy Igg

Sponsor

Emory University

Collaborator

The Leukemia and Lymphoma Society

Location

United States, Georgia

---

ClinicalTrials.gov Identifier: NCT03820817

Official Title: Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy

First Posted : January 29, 2019

https://clinicaltrials.gov/ct2/show/NCT03820817

---

Drug: Rifaximin

---

Location

United States, Georgia